AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

22.05.2008 07:40:06
Amsterdam Molecular Therapeutics B.V: Amsterdam, The Netherlands (ots/PRNewswire) - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from La Sapienza University in Rome, Italy, to their ...

Lesen Sie hier weiter... | Drucken | PDF

Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-to-Treat Hepatitis C Patients
European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
Agreement With Leading CO2 Capture Technology Firm, HTC Purenergy, Puts Doosan Babcock and the UK at Forefront of Carbon Capture Technology
Technology Reviewüber Tiere als Pharma-Fabriken / Medikamente von Ziegen, Kühen und Hühnern
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Recent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
PREZISTA(R) (darunavir) Receives Expanded Marketing Authorisation in the European Union for Treatment-Experienced Adults With HIV-1
Inovelon(R) a New Treatment for Lennox-Gastaut Syndrome Reduces Drop Attacks by Over 40%

Presseportal: Amsterdam Molecular Therapeutics B.V

Die Datenbank für Pressematerial in Text, Bild und Ton von mehr als 15.000 Presse AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

Presseportal.de - Amsterdam Molecular Therapeutics B.V

AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity.AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy